These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

968 related articles for article (PubMed ID: 27852009)

  • 1. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
    Chistiakov DA; Orekhov AN; Bobryshev YV
    Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
    Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic-related therapeutic challenges in cardiovascular disease.
    Schiano C; Vietri MT; Grimaldi V; Picascia A; De Pascale MR; Napoli C
    Trends Pharmacol Sci; 2015 Apr; 36(4):226-35. PubMed ID: 25758254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Regulatory Mechanisms Induced by Resveratrol.
    Fernandes GFS; Silva GDB; Pavan AR; Chiba DE; Chin CM; Dos Santos JL
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29104258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy.
    Myasoedova VA; Sukhorukov V; Grechko AV; Zhang D; Romanenko E; Orekhov V; Orekhov AN
    Curr Pharm Des; 2019; 25(6):635-641. PubMed ID: 30950345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting epigenetic DNA and histone modifications to treat kidney disease.
    Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
    Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetics and cancer treatment.
    Kristensen LS; Nielsen HM; Hansen LL
    Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
    Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
    Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic regulation of gene expression as an anticancer drug target.
    Ferguson LR; Tatham AL; Lin Z; Denny WA
    Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.
    Vahid F; Zand H; Nosrat-Mirshekarlou E; Najafi R; Hekmatdoost A
    Gene; 2015 May; 562(1):8-15. PubMed ID: 25701602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of epigenetic agents and natural nutrition products targeting DNA methyltransferase, histone deacetylases and microRNAs.
    Huang D; Cui L; Ahmed S; Zainab F; Wu Q; Wang X; Yuan Z
    Food Chem Toxicol; 2019 Jan; 123():574-594. PubMed ID: 30408543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of epigenetics in the management of cardiovascular disease: a review.
    Cao Y; Lu L; Liu M; Li XC; Sun RR; Zheng Y; Zhang PY
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3097-104. PubMed ID: 25392111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
    Vendetti FP; Rudin CM
    Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of epigenetic therapy in cancer.
    Hellebrekers DM; Griffioen AW; van Engeland M
    Biochim Biophys Acta; 2007 Jan; 1775(1):76-91. PubMed ID: 16930846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
    Katarzyna R; Lucyna B
    J Cancer Res Ther; 2019; 15(5):961-970. PubMed ID: 31603095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic-based therapies in cancer: progress to date.
    Song SH; Han SW; Bang YJ
    Drugs; 2011 Dec; 71(18):2391-403. PubMed ID: 22141383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DNA methyltransferase inhibitors * histone deacetylase inhibitors].
    Kikuchi J; Furukawa Y
    Nihon Rinsho; 2014 Jun; 72(6):1136-42. PubMed ID: 25016817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells.
    Sundaram MK; Ansari MZ; Al Mutery A; Ashraf M; Nasab R; Rai S; Rais N; Hussain A
    Anticancer Agents Med Chem; 2018; 18(3):412-421. PubMed ID: 28925878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
    Oh S; Ko JY; Oh C; Yoo KH
    Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.